Serum amyloid A and atherosclerosis. Issue 5 (October 2016)

• Record Type: Journal Article
• Authors: Getz, Godfrey S.; Krishack, Paulette A.; Reardon, Catherine A.
• Is Part Of: Current opinion in lipidology. Volume 27:Issue 5(2016:Oct.)
• Publication Date: 2016-10
• Subjects: atherosclerosis -- HDL -- inflammation -- serum amyloid A; Lipids -- Periodicals; 572.574
• DOI: 10.1097/MOL.0000000000000331
• Languages: English
• ISSNs: 1473-6535

Abstract

Abstract : Purpose of review: Atherosclerosis is a chronic inflammation associated with increased expression of the acute phase isoforms of serum amyloid A (SAA) and in humans is a plasma biomarker for future cardiovascular events. However, whether SAA is only a biomarker or participates in the development of cardiovascular disease is not well characterized. The purpose of this review is to summarize putative functions of SAA relevant to atherogenesis and in-vivo murine studies that directly examine the effect of SAA on atherosclerosis. Recent findings: Modulation of the expression of SAA1 and/or SAA2 in murine models of atherosclerosis suggests that SAA promotes early atherogenesis. SAA secreted from bone-marrow-derived cells contributes to this antiatherogenic phenotype. SAA also promotes angiotensin-induced abdominal aneurysm in atherogenic mouse models. The reduction in atherosclerosis may be due, at least in part, to remodeling of the acute phase HDL to reduce its capacity to promote cholesterol efflux and reduce its anti-inflammatory ability. Summary: SAA is more than a marker of cardiovascular disease and is a participant in the early atherogenic process.